BWAY NASDAQ
Credit Risk of going bust: lower than 84% of companies Debt: 1.6% of company value Bonds: none of note held by US funds details ▾
Total debt $7.1M against a stock market value of $439.7M.
Distance to default 11.01 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.2M (short-term plus half of long-term), stock volatility 52.6%; Altman Z'' 3.36. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Jerusalem, JM 9777516
IL
BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's clientele primarily comprises medical professionals, hospitals, and medical centers specializing in psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Moiseyev Gilad | S-Sale | 5,000 | — | 2026-06-15 |
| Mitrany Rayten Micha | S-Sale | 7,980 | — | 2026-05-26 |
| Moiseyev Gilad | M-Exempt | 7,500 | — | 2026-05-25 |
| Moiseyev Gilad | F-InKind | 1,902 | — | 2026-05-25 |
| Moiseyev Gilad | M-Exempt | 7,500 | — | 2026-05-25 |